학술논문
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Document Type
Article
Author
Varkaris, A.; Lormil, B.; Walters, W.P.; Pazolli, E.; Gunaydin, H.; Pierce, L.; Boezio, A.A.; Bulku, A.; DiPietro, L.; Fridrich, C.; Holliday, M.; Hunter, T.L.; Iskandar, A.; LaRochelle, J.R.; Lescarbeau, A.; Llambi, F.; Mader, M.M.; Mar, B.G.; Martin, I.; McLean, T.H.; Michelsen, K.; Puente-Poushnejad, E.; Raynor, K.; Rogala, D.; Samadani, R.; Shortsleeves, K.; Swaminathan, S.; Tan, G.; Tang, Y.; Valverde, R.; Wehrenberg, B.; Wilbur, J.; Williams, B.R.; Zeng, H.; Zhang, H.; Wolf, B.B.; Bergstrom, D.A.; Watters, J.; Fortin, P.D.; Kipp, D.R.; Wang, Q.; Giordanetto, F.; Pechersky, Y.; Shaw, D.E.; Frost, A.; Fraser, J.S.; Hamilton, E.P.; Harris, K.; Ji, Y.; Larivée, A.; Schram, A.M.; Tajmir, S.
Source
In: Cancer discovery . (Cancer discovery, 8 February 2024, 14(2):240-257)
Subject
Language
English
ISSN
21598290